Saroglitazar: Dual PPAR Agonist for Lipids & NASH

Saroglitazar is an innovative pharmaceutical agent classified as a dual PPAR agonist ($\alpha$ and $\gamma$). This unique mechanism allows it to simultaneously improve lipid metabolism (lowering triglycerides) and enhance insulin sensitivity.

The drug is designed to treat complex metabolic disorders, including diabetic dyslipidemia and non-alcoholic steatohepatitis (NASH). On Unifarm, you can find a list of medications containing this active ingredient.

Wikipedia page

Indications

Diabetic Dyslipidemia: Treatment of hypertriglyceridemia in patients with Type 2 Diabetes Mellitus not controlled by statin therapy alone.
Hypertriglyceridemia: High blood triglyceride levels unrelated to diabetes.
Non-Alcoholic Steatohepatitis (NASH): To reduce liver inflammation and fibrosis.
Non-Alcoholic Fatty Liver Disease (NAFLD): In patients with metabolic comorbidities.

Dosage and administration

Saroglitazar medications are taken orally, typically once daily, with or without food.

Standard Regimen:

The recommended dose is 4 mg once daily.
The tablet should be swallowed whole with water.
No dose adjustment is required for elderly patients.

The duration of treatment and the need for combination with statins are determined by the physician.

Hypersensitivity to the drug components.
Severe hepatic impairment or decompensated liver disease (despite indication for NASH, severe forms require caution).
Severe renal impairment.
Pregnancy and breastfeeding.
Age under 18 years.